Jacobio Pharmaceuticals (HKG:1167) plans to repurchase shares worth up to HK$100 million under a mandate approved by shareholders at its annual general meeting on June 5, according to a Monday Hong Kong bourse filing.
The company is authorized to repurchase up to 78.4 million shares, representing 10% of its issued share capital, excluding treasury shares.
Jacobio said the buybacks will be funded from internal resources and may continue until the mandate expires, subject to market conditions.